The outcome of such trials is typically kept secret from investors and even company executives. " Right now the whole value of this thing swings on a bet on the study results," he said. In San Francisco this week, Mr. Wilkinson said he had received interest in a possible acquisition from about 20 "high grade" pharmaceutical companies. 